Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis
about
Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitisNew steroids and new salicylates in inflammatory bowel disease: a critical appraisalOral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study.Efficacy and safety of rectal 5-aminosalicylic acid versus corticosteroids in active distal ulcerative colitis: a systematic review and network meta-analysisDrug therapy of ulcerative colitisDNA flow cytometric evaluation of cell cycle distribution in ulcerative colitis: a proposed method for assessing severity of disease.Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis.Therapeutic strategies for the management of ulcerative colitis.High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: results of a meta-analysis of clinical trials.Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis.Systematic Review: Rectal Therapies for the Treatment of Distal Forms of Ulcerative Colitis.Assessment of disease severity and activity in inflammatory bowel disease.What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?Anti-inflammatory effects of 5-aminosalicylic acid conjugates with chenodeoxycholic acid and ursodeoxycholic acid on carrageenan-induced colitis in guinea-pigs.A new mesalazine foam enema (Claversal Foam) compared with a standard liquid enema in patients with active distal ulcerative colitis.Protective effects of black cumin (Nigella sativa) oil on TNBS-induced experimental colitis in rats.Efficacy of zinc-carnosine chelate compound, Polaprezinc, enemas in patients with ulcerative colitis.
P2860
Q24240567-C1F5D330-8218-4EC2-80B5-ACFDEE643507Q28192793-E9A134EC-296B-4D53-A9C1-A24337982D04Q31811146-94DDF147-FFEF-40A5-943C-BD1273E0174FQ33600845-F3868C12-47AA-449A-BA0B-BA0192299E3DQ34403155-FF49941C-2216-4EE2-AC00-1AF7F920519BQ34407435-2B148749-542C-41AE-B062-234913E5ACDBQ34425918-762E7BC2-1979-44E0-9B75-104716C1D86DQ35361187-3C1EC8DC-83A9-434C-A73A-0C8943CA4064Q37318035-8A6060D3-31B2-46CA-88AB-0E38F417E618Q37993821-F14DC672-3DA5-4FE8-9CAF-D1C614E073ACQ38014364-446EEB51-9210-4906-BF04-9326DAC369B3Q38505808-FC1E7C65-7569-43F6-8336-9521F76F278FQ40874249-FF3ADEE0-ACAC-4B39-9664-09D146A33AE0Q41903886-E790DDA6-7985-45C2-8C9E-158D78A4B490Q43862277-B7C4E948-6B59-4F0A-8E7C-C95166D9E06CQ43904263-6A7EBAEF-4C99-42D1-8B1A-80D1D74BB89BQ48340059-393DF619-7813-45EA-A160-4DA12D87A5CCQ50748992-385DB3F0-7FC5-4B06-BC99-6202A320CA0F
P2860
Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis
description
1991 nî lūn-bûn
@nan
1991 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Optimum dosage of 5-aminosalic ...... with active ulcerative colitis
@ast
Optimum dosage of 5-aminosalic ...... with active ulcerative colitis
@en
Optimum dosage of 5-aminosalic ...... with active ulcerative colitis
@nl
type
label
Optimum dosage of 5-aminosalic ...... with active ulcerative colitis
@ast
Optimum dosage of 5-aminosalic ...... with active ulcerative colitis
@en
Optimum dosage of 5-aminosalic ...... with active ulcerative colitis
@nl
prefLabel
Optimum dosage of 5-aminosalic ...... with active ulcerative colitis
@ast
Optimum dosage of 5-aminosalic ...... with active ulcerative colitis
@en
Optimum dosage of 5-aminosalic ...... with active ulcerative colitis
@nl
P2093
P2860
P356
P1433
P1476
Optimum dosage of 5-aminosalic ...... with active ulcerative colitis
@en
P2093
Belluzzi A
Brignola C
Campieri M
Gionchetti P
Miglioli M
Tampieri M
P2860
P304
P356
10.1136/GUT.32.8.929
P407
P577
1991-08-01T00:00:00Z